Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk

Bibliography

• Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 2013;1:59-70
   PubMed Web of Science ®Google Scholar
• Devogelaer JP, Goemaere S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006;17:8-19
   PubMed Web of Science ®Google Scholar
• Weinstein RS. Clinical practice. Glucocorticoid induced bone disease. N Engl J Med 2011;365:62-70
   PubMed Web of Science ®Google Scholar
• Hansen KE, Wilson HA, Zapalowski C, et al. Uncertainties in the prevention and treatment of glucocorticosteroid induced osteoporosis. J Bone Miner Res 2011;26:1989-96
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM 2000;93:105-11
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000
   PubMed Web of Science ®Google Scholar
• Adler RA. Glucocorticoid-induced osteoporosis: management update. Curr Osteoporos Rep 2010;8:10-14
   PubMedGoogle Scholar
• Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-28
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:893-9
   PubMed Web of Science ®Google Scholar
• Reid IR, Evans MC, Wattie DJ, et al. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporos Int 1992;2:103-5
   PubMed Web of Science ®Google Scholar
• Stevens A, Ray DW, Zeggini E, et al. Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. J Clin Endocrinol Metab 2004;89:892-7
   PubMed Web of Science ®Google Scholar
• Warriner AH, Saag KG. Prevention and treatment of bone changes associated with exposure to glucocorticoids. Curr Osteoporos Rep 2013;11:341-7
   PubMedGoogle Scholar
• Majumdar SR, Lix LM, Yogendran M, et al. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008). J Clin Endocrinol Metab 2012;97:1236-42
   PubMed Web of Science ®Google Scholar
• Chitre MM, Hayes W. 3-year results of a member and physician intervention to reduce risk associated with glucocorticoid induced osteoporosis in a health plan. J Manag Care Pharm 2008;14:281-90
   PubMed Web of Science ®Google Scholar
• Solomon DH, Katz JN, La Tourette AM, Coblyn JS. Multifaceted intervention to improve rheumatologists’ management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum 2004;51:383-7
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-9
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Burmester GR, Straub RH, et al. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011;63:1-9
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-82
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Adachi JD, Cooper C, et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2012;91:225-43
   PubMed Web of Science ®Google Scholar
• Prummel MF, Wiersinga WM, Lips P, et al. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991;72:382-6
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-82
   PubMed Web of Science ®Google Scholar
• Bultink IEM, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 2013;14:185-97
   PubMed Web of Science ®Google Scholar
• Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010;6:82-8
   PubMed Web of Science ®Google Scholar
• Ohnaka K, Tanabe M, Kawate H, et al. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005;329:177-81
   PubMed Web of Science ®Google Scholar
• Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19-39
   PubMed Web of Science ®Google Scholar
• Wang FS, Ko JY, Yeh DW, et al. Modulation of Dickkopf-1 attenuate glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 2008;149:1793-801
   PubMed Web of Science ®Google Scholar
• Hayashi K, Yamaguchi T, Yano S, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid- induced osteoporosis. Biochem Biophys Res Commun 2009;379:261-6
   PubMed Web of Science ®Google Scholar
• Yao W, Cheng Z, Busse C, et al. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 2008;58:1674-86
   PubMed Web of Science ®Google Scholar
• Den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid- induced osteoporosis. Curr Rheumatol Rep 2011;13:233-40
   PubMed Web of Science ®Google Scholar
• Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751-64
   PubMed Web of Science ®Google Scholar
• Smith E, Frenkel B. Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3beta-dependent and –independent manner. J Biol Chem 2005;280:2388-94
   PubMed Web of Science ®Google Scholar
• Ito S, Suzuki N, Kato S, et al. Glucocorticoids induce the differentiation of a mesenchymal progenitor cell line, ROB-C26 into adipocytes and osteoblasts, but fail to induce terminal osteoblast differentiation. Bone 2007;40:84-92
   PubMed Web of Science ®Google Scholar
• Pereira RC, Delany AM, Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation correlation with CCAAT-enhancer binding protein expression. Bone 2002;30:685-91
   PubMed Web of Science ®Google Scholar
• Pereira RC, Delany AM, Canalis E. CCAAT/enhancer binding protein homologous protein (DDIT3) induces osteoblastic cell differentiation. Endocrinology 2004;145:1952-60
   PubMed Web of Science ®Google Scholar
• Canalis E. Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae. Endocrinology 1983;112:931-9
   PubMed Web of Science ®Google Scholar
• Canalis E. Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep 2005;3:98-102
   PubMedGoogle Scholar
• Wu Z, Bucher NLR, Farmer SR. Induction of peroxisome proliferator-activated receptor g during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPh, C/EBPy, and glucocorticoids. Mol Cell Biol 1996;16:4128-36
   PubMed Web of Science ®Google Scholar
• O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004;145:1835-41
   PubMed Web of Science ®Google Scholar
• Yun SI, Yoon HY, Jeong SY, Chung YS. Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab 2009;27:140-8
   PubMed Web of Science ®Google Scholar
• Bellido T. Antagonistic interplay between mechanical forces and glucocorticoids in bone: a tale of kinases. J Cell Biochem 2010;111:1-6
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Manolagas SC, Bellido T. Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival: evidence for inside-out signaling leading to anoikis. J Biol Chem 2007;282:24120-30
   PubMed Web of Science ®Google Scholar
• Xia X, Kar R, Gluhak-Heinrich J, et al. Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res 2010;25:2479-88
   PubMed Web of Science ®Google Scholar
• Rochefort GY, Benhamou CL. Osteocyte are not only mechanoreceptor cells. Int J Numer Method Biomed Eng 2013;10):1082-8
   PubMed Web of Science ®Google Scholar
• Rochefort GY, Pallu S, Benhamou CL. Osteocyte: the unrecognized side of bone tissue. Osteoporosis Int 2010;21:1457-69
   PubMed Web of Science ®Google Scholar
• Lane NE, Yao W, Balooch M, et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 2006;21:466-76
   PubMed Web of Science ®Google Scholar
• Jia D, O’Brien CA, Stewart SA, et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006;147:5592-9
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999;140:4382-9
   PubMed Web of Science ®Google Scholar
• Kondo T, Kitazawa R, Yamaguchi A, Kitazawa S. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem 2008;103:335-45
   PubMed Web of Science ®Google Scholar
• Dovio A, Perazzolo L, Saba L, et al. High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur J Endocrinol 2006;154:745-51
   PubMed Web of Science ®Google Scholar
• Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006;116:2152-60
   PubMed Web of Science ®Google Scholar
• Schakman O, Kalista S, Barbé C, et al. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013;45:2163-72
   PubMed Web of Science ®Google Scholar
• Natsui K, Tanaka K, Suda M, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 2006;17:105-8
   PubMed Web of Science ®Google Scholar
• Delany AM, Gabbitas BY, Canalis E. Cortisol down regulates osteoblast 1(I) procollagen mRNA by transcriptional and post-transcriptional mechanisms. J Cell Biochem 1995;57:488-94
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87
   PubMed Web of Science ®Google Scholar
• Abadie EC, Devogealer JP, Ringe JD, et al. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. Semin Arthritis Rheum 2005;35:1-4
   PubMed Web of Science ®Google Scholar
• Cooper MS, Rabbitt EH, Goddard PE, et al. Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 2002;17:979-86
   PubMed Web of Science ®Google Scholar
• Russcher H, Smit P, van den Akker EL, et al. Two polymorphisms in the glucocorticoid receptor gene directly aff ect glucocorticoid-regulated gene expression. J Clin Endocrinol Metab 2005;90:5804-10
   PubMed Web of Science ®Google Scholar
• Venuturupalli SR, Sacks W. Review of new guidelines for the management of glucocorticoid induced osteoporosis. Curr Osteoporos Rep 2013;11:357-64
   PubMedGoogle Scholar
• Nawata H, Soen S, Takayanagi R, et al. Guidelines on the management and treatment of glucocorticoid induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 2005;23:105-9
   PubMed Web of Science ®Google Scholar
• Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003;163:2619-24
   PubMed Web of Science ®Google Scholar
• Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012;23:2257-76
   PubMed Web of Science ®Google Scholar
• Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 2012;52:580-93
   PubMed Web of Science ®Google Scholar
• Geusens PP, Suzuki Y, Nawata H, et al. Guidelines on the management and treatment of the glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 2014;32(4):337-50
   PubMed Web of Science ®Google Scholar
• Geusens PP, de Nijs RN, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 2004;63:324-5
   PubMed Web of Science ®Google Scholar
• Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010;62:1515-26
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-97
   PubMed Web of Science ®Google Scholar
• Deal CL. Recent recommendations on steroid-induced osteoporosis: more targeted, but more complicated. Cleve Clin J Med 2013;80:117-25
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011;22:809-16
   PubMed Web of Science ®Google Scholar
• Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012;23:2257-76
   PubMed Web of Science ®Google Scholar
• Leib ES, Saag KG, Adachi JD, et al. Official positions for FRAX ((R)) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX((R)) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX (R). J Clin Densitom 2011;14:212-19
   PubMed Web of Science ®Google Scholar
• Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993;119:963-8
   PubMed Web of Science ®Google Scholar
• Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008;197:1-10
   PubMed Web of Science ®Google Scholar
• Gluck OS, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 1981;24:892-8
   PubMed Web of Science ®Google Scholar
• Frediani B, Falsetti P, Bisogno S, et al. Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J Rheumatol 2004;31:1083-7
   PubMed Web of Science ®Google Scholar
• Perez AV, Picotto G, Carpentieri AR, et al. Minireview on regulation of intestinal calcium absorption. Emphasis on molecular mechanisms of transcellular pathway. Digestion 2008;77:22-34
   PubMed Web of Science ®Google Scholar
• Ritz E, Kreusser W, Rambausek M. Effects of glucocorticoids on calcium and phosphate excretion. Adv Exp Med Biol 1984;171:381-97
   PubMed Web of Science ®Google Scholar
• Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 1997;61:266-71
   PubMed Web of Science ®Google Scholar
• Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001;16:104-12
   PubMed Web of Science ®Google Scholar
• Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7
   PubMed Web of Science ®Google Scholar
• Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized,double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18
   PubMed Web of Science ®Google Scholar
• Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52
   PubMed Web of Science ®Google Scholar
• Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004;15:301-10
   PubMed Web of Science ®Google Scholar
• Richy F, Schacht E, Bruyere O, et al. Vitamin D analogs vs native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 2005;76:176-86
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996;10:777-86
   PubMed Web of Science ®Google Scholar
• Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis—a randomized, doubleblind, placebo-controlled trial. Ann Intern Med 1996;125:961-8
   PubMed Web of Science ®Google Scholar
• Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid-induced osteoporosis: a 3-year follow-up. J Rheumatol 1996;23:995-1000
   PubMed Web of Science ®Google Scholar
• Bijlsma JW, Raymakers JA, Mosch C, et al. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin Exp Rheumatol 1988;6:113-19
   PubMed Web of Science ®Google Scholar
• Di Munno O, Beghe F, Favini P, et al. Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxyvitamin D and calcium. Clin Rheumatol 1989;8:202-7
   PubMed Web of Science ®Google Scholar
• Tałałaj M, Gradowska L, Marcinowska-Suchowierska E, et al. Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplant Proc 1996;28:3485-7
   PubMed Web of Science ®Google Scholar
• Dykman TR, Haralson KM, Gluck OS, et al. Effect of oral 1,25- dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984;27:1336-43
   PubMed Web of Science ®Google Scholar
• Sambrook P, Henderson NK, Keogh A, et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000;15:1818-24
   PubMed Web of Science ®Google Scholar
• Ringe JD, Cöster A, Meng T, et al. Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 1999;65:337-40
   PubMed Web of Science ®Google Scholar
• Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid- induced osteoporosis. Cochrane Database Syst Rev 2000(2):CD000952
   Google Scholar
• Amin S, LaValley MP, Simms RW, Felson DT. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 1999;42:1740-51
   PubMed Web of Science ®Google Scholar
• Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-9
   PubMed Web of Science ®Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39
   PubMed Web of Science ®Google Scholar
• Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253-63
   PubMed Web of Science ®Google Scholar
• Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate inthe treatment of corticosteroid induced osteoporosis in men andwomen:a randomized trial. European Corticosteroid Induced Osteoporosis Treatment Study. J Bone Miner Res 2000;15:1006-13
   PubMed Web of Science ®Google Scholar
• Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporosis Int 1999;9:75-81
   PubMed Web of Science ®Google Scholar
• De Nijs RN, Jacobs JW, Algra A, et al. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004;15:589-602
   PubMed Web of Science ®Google Scholar
• De Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:675-84
   PubMed Web of Science ®Google Scholar
• Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003;18:919-24
   PubMed Web of Science ®Google Scholar
• Lips P. Relative value of 25(OH)D and 1,25(OH)2D measurements. J Bone Miner Res 2007;22:1668-71
   PubMed Web of Science ®Google Scholar
• Healey JH, Paget SA, Williams-Russo P, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996;58:73-80
   PubMed Web of Science ®Google Scholar
• Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987;33:35-9
   PubMed Web of Science ®Google Scholar
• Tascioglu F, Colak O, Armagan O, et al. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. Rheumatol Int 2005;26:21-9
   PubMed Web of Science ®Google Scholar
• Adachi JD, Bensen WG, Bell MJ, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997;36:255-9
   PubMedGoogle Scholar
• Kapetanakis EI, Antonopoulos AS, Antoniou TA, et al. Effect of long-term calcitonin administration on steroid-induced osteoporosis after cardiac transplantation. J Heart Lung Transplant 2005;24:526-32
   PubMed Web of Science ®Google Scholar
• Rizzato G, Tosi G, Schiraldi G, et al. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis 1988;5:99-103
   PubMedGoogle Scholar
• Montemurro L, Schiraldi G, Fraioli P, et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991;49:71-6
   PubMed Web of Science ®Google Scholar
• Luengo M, Pons F, Martinez de Osaba MJ, Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 1994;49:1099-102
   PubMed Web of Science ®Google Scholar
• Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000(2):CD001983
   Google Scholar
• Plotkin L, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 2006;39:443-52
   PubMed Web of Science ®Google Scholar
• Roux C, Oriente P, Laan R, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 1998;83:1128-33
   PubMed Web of Science ®Google Scholar
• Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving GC: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11
   PubMed Web of Science ®Google Scholar
• Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85
   PubMed Web of Science ®Google Scholar
• Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized,placebo-controlled clinical trial. J Rheumatol 2009;36:1705-14
   PubMed Web of Science ®Google Scholar
• Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003;14:801-7
   PubMed Web of Science ®Google Scholar
• Furukawa F, Kaminaka C, Ikeda T, et al. Preliminary study of etidronate for prevention of corticosteroid-induced osteoporosis caused by oral glucocorticoid therapy. Clin Exp Dermatol 2011;36:165-8
   PubMed Web of Science ®Google Scholar
• Sebaldt RJ, Ioannidis G, Adachi JD, et al. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis. J Rheumatol 1999;26:1545-9
   PubMed Web of Science ®Google Scholar
• Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42
   PubMed Web of Science ®Google Scholar
• Sebaldt RJ, Adachi JD, Bensen WG, et al. Intermittent cyclic therapy with etidronate prevents corticosteroid-induced bone loss: two years of follow-up. Scand J Rheumatol Suppl 1996;103:91-3
   PubMedGoogle Scholar
• Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50
   PubMedGoogle Scholar
• Fujita T, Satomura A, Hidaka M, et al. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy. Calcif Tissue Int 2000;66:195-9
   PubMed Web of Science ®Google Scholar
• Loddenkemper K, Grauer A, Burmester GR, Buttgereit F. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases. Clin Exp Rheumatol 2003;21:19-26
   PubMed Web of Science ®Google Scholar
• Skingle SJ, Crisp AJ. Increased bone density in patients on steroids with etidronate. Lancet 1994;344:543-4
   PubMed Web of Science ®Google Scholar
• Jenkins EA, Walker-Bone KE, Wood A, et al. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 1999;28:152-6
   PubMed Web of Science ®Google Scholar
• Geusens P, Dequeker J, Vanhoof J, et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Ann Rheum Dis 1998;57:724-7
   PubMed Web of Science ®Google Scholar
• Pitt P, Li F, Todd P, et al. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax 1998;53:351-6
   PubMed Web of Science ®Google Scholar
• Cortet B, Hachulla E, Barton I, et al. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Rev Rhum Engl Ed 1999;66:214-19
   PubMedGoogle Scholar
• Jinnouchi Y. Efficacy of intermittent etidronate therapy for corticosteroid-induced osteoporosis in patients with diffuse connective tissue disease. Kurume Med J 2000;47:219-24
   PubMedGoogle Scholar
• Sato S, Takada T, Katsuki Y, et al. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup. J Rheumatol 2008;35:142-6
   PubMed Web of Science ®Google Scholar
• Campbell IA, Douglas JG, Francis RM, et al. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 2004;59:761-8
   PubMed Web of Science ®Google Scholar
• Sato S, Ohosone Y, Suwa A, et al. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. J Rheumatol 2003;30:2673-9
   PubMed Web of Science ®Google Scholar
• Cauza E, Etemad M, Winkler F, et al. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther 2004;29:431-6
   PubMed Web of Science ®Google Scholar
• Kim SD, Cho BS. Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy. Nephron Clin Pract 2006;102(3-4):c81-7
   PubMed Web of Science ®Google Scholar
• Nzeusseu Toukap A, Depresseux G, Devogelaer JP, Houssiau FA. Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients. Lupus 2005;14:517-20
   PubMed Web of Science ®Google Scholar
• Noguera A, Ros JB, Pavía C, et al. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab 2003;16:529-36
   PubMed Web of Science ®Google Scholar
• Reid IR, Schooler BA, Stewart AW. Prevention of glucocorticoid-induced osteoporosis. J Bone Miner Res 1990;5:619-23
   PubMed Web of Science ®Google Scholar
• Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988;1:143-6
   PubMed Web of Science ®Google Scholar
• Reid IR, Heap SW, King AR, Ibbertson HK. Two-year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis. Lancet 1988;2:1144
   PubMed Web of Science ®Google Scholar
• Emkey R, Delmas PD, Goemaere S, et al. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study. Arthritis Rheum 2003;48:1102-8
   PubMed Web of Science ®Google Scholar
• Okada Y, Nawata M, Nakayamada S, et al. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol 2008;35:2249-54
   PubMed Web of Science ®Google Scholar
• Lems WF, Lodder MC, Lips P, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2006;17(5):716-23
   PubMed Web of Science ®Google Scholar
• Kaji H, Kuroki Y, Murakawa Y, et al. Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study. Osteoporos Int 2010;21:1565-71
   PubMed Web of Science ®Google Scholar
• Tee SI, Yosipovitch G, Chan YC, et al. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. Arch Dermatol 2012;148:307-14
   PubMed Web of Science ®Google Scholar
• Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001;69:242-7
   PubMed Web of Science ®Google Scholar
• Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000;11:331-7
   PubMed Web of Science ®Google Scholar
• Mok CC, Tong KH, To CH, et al. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Osteoporos Int 2008;19:357-64
   PubMed Web of Science ®Google Scholar
• Thomas T, Horlait S, Ringe JD, et al. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice. Osteoporos Int 2013;24:263-9
   PubMed Web of Science ®Google Scholar
• Takei T, Itabashi M, Tsukada M, et al. Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome. Intern Med 2010;49:2065-70
   PubMed Web of Science ®Google Scholar
• Kriel MH, Tobias JH, Creed TJ, et al. Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease. Osteoporos Int 2010;21:507-13
   PubMed Web of Science ®Google Scholar
• Katayama K, Matsuno T. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study. Clin Drug Investig 2008;28:149-58
   PubMed Web of Science ®Google Scholar
• Lange U, Illgner U, Teichmann J, Schleenbecker H. Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis: a prospective study. Int J Clin Pharmacol Res 2004;24:33-8
   PubMedGoogle Scholar
• Roux C, Reid DM, Devogelaer JP, et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int 2012;23:1083-90
   PubMed Web of Science ®Google Scholar
• Sambrook PN, Roux C, Devogelaer JP, et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with Risedronate. Bone 2012;50:289-95
   PubMed Web of Science ®Google Scholar
• Devogelaer JP, Sambrook P, Reid DM, et al. Effect on bone turnover markers of once-yearl intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. Rheumatology 2013;52:1058-69
   PubMed Web of Science ®Google Scholar
• Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003;14:801-7
   PubMed Web of Science ®Google Scholar
• Li EK, Zhu TY, Hung VY, et al. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Res Ther 2010;12:R198
   PubMedGoogle Scholar
• Hakala M, Kröger H, Valleala H, et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scand J Rheumatol 2012;41:260-6
   PubMed Web of Science ®Google Scholar
• Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, et al. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 2009;24:1335-44
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009;20:2095-104
   PubMed Web of Science ®Google Scholar
• Devogelaer JP, Adler RA, Recknor C, et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 2010;37:141-8
   PubMed Web of Science ®Google Scholar
• Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009;60:3346-55
   PubMed Web of Science ®Google Scholar
• Eastell R, Chen P, Saag KG, et al. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 2010;46:929-34
   PubMed Web of Science ®Google Scholar
• Burshell AL, Möricke R, Correa-Rotter R, et al. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 2010;46:935-9
   PubMed Web of Science ®Google Scholar
• Karras D, Stoykov I, Lems WF, et al. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoiduse: 3-year results from the EFOS study. J Rheumatol 2012;39:600-9
   PubMed Web of Science ®Google Scholar
• Glüer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 2013;28:1355-68
   PubMed Web of Science ®Google Scholar
• Farahmand P, Marin F, Hawkins F, et al. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int 2013;24:2971-81
   PubMed Web of Science ®Google Scholar
• Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-33
   PubMed Web of Science ®Google Scholar
• Sun P, Cai DH, Li QN, et al. Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats. Calcif Tissue Int 2010;86:495-501
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Zeitz U, Schoppet M, et al. Prevention of glucocorticoid- induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 2009;60:1427-37
   PubMed Web of Science ®Google Scholar
• Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010;69:872-5
   PubMed Web of Science ®Google Scholar